98%
921
2 minutes
20
Heart valve replacement surgeries are performed on patients suffering from abnormal heart valve function. In these operations, the problematic tissue is replaced with mechanical valves or with bioprosthetics that are being developed. The thrombotic effect of mechanical valves, reflecting the need for lifelong use of anticoagulation drugs, and the short-lived nature of biological valves make these two types of valves problematic. In addition, they cannot adapt to the somatic growth of young patients. Although decellularized scaffolds have shown some promise, a successful translation has so far evaded. Although decellularized porcine xenografts have been extensively studied in the literature, they have several disadvantages, such as a propensity for calcification in the implant model, a risk of porcine endogenous retrovirus (PERV) infection, and a high xenoantigen density. As seen in clinical data, it is clear that there are biocompatibility problems in almost all studies. However, since decellularized sheep heart valves have not been tried in the clinic, a large data pool could not be established. This review compares and contrasts decellularized porcine and sheep xenografts for heart valve tissue engineering. It reveals that decellularized sheep heart valves can be an alternative to pigs in terms of biocompatibility. In addition, it highlights the potential advantages of bioinks derived from the decellularized extracellular matrix in 3D bioprinting technology, emphasizing that they can be a new alternative for the application. We also outline the future prospects of using sheep xenografts for heart valve tissue engineering.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558188 | PMC |
http://dx.doi.org/10.1002/btm2.10695 | DOI Listing |
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Patients with atrial fibrillation, venous thrombosis, and mechanical heart valve (MHV) regularly undergo procedures on a daily basis, for which they require bridging anticoagulation, but this poses significant challenges. Bridging anticoagulation involves temporary interruption of long-term anticoagulation therapy for procedures and continued overlap with short-acting anticoagulants during perioperative period. Heparin-based agents are often used for overlapping in perioperative period to reduce the risk of thromboembolism, but the evidence for benefit particularly in patients with MHV remains limited.
View Article and Find Full Text PDFArq Bras Cardiol
September 2025
Escola Bahiana de Medicina e Saúde Pública, Salvador, BA - Brasil.
Background: Chronic kidney disease (CKD) is associated with a higher prevalence of valvular diseases and increased mortality from cardiovascular causes. Factors that influence the genesis of cardiac valve calcification (CVC) in these patients are not well-defined.
Objective: To determine the risk factors for valvular calcification in patients with CKD.
J Invasive Cardiol
September 2025
Division of Cardiology, Mount Sinai Heart Fuster Hospital, Icahn School of Medicine at Mount Sinai, New York, New York. Email:
JACC Case Rep
September 2025
Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, USA; Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Loeys-Dietz syndrome (LDS) is a rare connective tissue disorder (CTD) with musculoskeletal, craniofacial, and cardiovascular features with a prevalence of approximately 1:50,000. Morbidity and mortality often occur earlier in patients with LDS compared to patients with other CTDs.
Case Summary: We present a teenager with subacute heart failure, 4/6 holosystolic murmur with diastolic rumble, facial differences, and arachnodactyly.
JACC Case Rep
September 2025
Department of Adult Cardiology, Jakaya Kikwete Cardiac Institute (JKCI), Dar es Salaam, Tanzania.
Background: Transcatheter pulmonary valve implantation (TPVI) has emerged as a viable alternative to surgical pulmonary valve replacement for patients with congenital heart disease and right ventricular outflow tract dysfunction. However, its adoption in low-resource settings has been limited.
Case Summary: We report the first successful TPVI procedures in Tanzania.